Patents by Inventor Francisca Wollerton Van Horck

Francisca Wollerton Van Horck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
    Publication number: 20230406935
    Abstract: The application relates to specific binding members which bind to programmed death-ligand 1 (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Application
    Filed: December 8, 2022
    Publication date: December 21, 2023
    Applicant: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • BISPECIFIC ANTIBODY FOR ICOS AND PD-L1
    Publication number: 20230348601
    Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
    Type: Application
    Filed: February 27, 2023
    Publication date: November 2, 2023
    Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederick AKELE
  • Bispecific antibody for ICOS and PD-L1
    Patent number: 11629189
    Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 18, 2023
    Assignee: KYMAB LIMITED
    Inventors: Matthew John McCourt, Richard Charles Alfred Sainson, Jamie Iain Campbell, Stephen John Arkinstall, Mihriban Tuna, Ryan Fiehler, Mustapha Faroudi, Fadi Badr, Francisca Wollerton Van Horck, Frederick Akele
  • FC binding fragments comprising a PD-L1 antigen-binding site
    Patent number: 11548948
    Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 10, 2023
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • BINDING MOLECULES BINDING PD-L1 AND LAG-3
    Publication number: 20220185894
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • LAG-3 binding members
    Patent number: 11214618
    Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
  • Binding molecules binding PD-L1 and LAG-3
    Patent number: 11214620
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis
  • FC BINDING FRAGMENTS COMPRISING A PD-L1 ANTIGEN-BINDING SITE
    Publication number: 20210139590
    Abstract: The application relates to specific binding members which bind to programmed death-ligand (PD-L1). The specific binding members preferably comprise a PD-L1 antigen-binding site located in structural loops of a constant domain of the specific binding member. The specific binding members find application, for example, in the treatment of cancer, as well as infectious diseases, inflammation, diseases and conditions associated with inflammation, and inflammatory diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 13, 2021
    Applicant: F-STAR BETA LIMITED
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Ryan Fiehler, Mustapha Faroudi, Frederick Akele, Fadi Badr, Cyril Privezentzev
  • BISPECIFIC ANTIBODY FOR ICOS AND PD-L1
    Publication number: 20200407446
    Abstract: Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 31, 2020
    Inventors: Matthew John MCCOURT, Richard Charles Alfred SAINSON, Jamie Iain CAMPBELL, Stephen John ARKINSTALL, Mihriban TUNA, Ryan FIEHLER, Mustapha FAROUDI, Fadi BADR, Francisca WOLLERTON VAN HORCK, Frederik AKELE
  • LAG-3 BINDING MEMBERS
    Publication number: 20190330344
    Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 31, 2019
    Applicant: F-STAR BETA LIMITED
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
  • BINDING MOLECULES BINDING PD-L1 AND LAG-3
    Publication number: 20190256602
    Abstract: The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 22, 2019
    Applicant: F-STAR DELTA LIMITED
    Inventors: Jamie Campbell, Nikole Sandy, Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Mustapha Faroudi, Natalie Fosh, Barbara Hebeis